Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

20 November 2018

Too few pharma companies prioritise access to medicines

Jessica Davis Plüss reports for swissinfo.ch on the finding from the 2018 Access to Medicine Index that progress in expanding access to medicines in poorer countries is concentrated among five pharmaceutical companies and on five diseases. She also highlights the performance of two Swiss companies in the ranking, Novartis and Roche.

Direct links

Read the full article

“Novartis was the top scorer in the category of general management, which includes aspects such as companies’ level of commitment and transparency. Where both Novartis and Roche performed weaker was on patents and licensing. Danny Edwards, the research lead for the index, explained that both Swiss companies are weaker in this analysis than other companies when it comes to sharing intellectual property (IP) with researchers in order to support R&D for low- and middle-income country needs.”

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved